Clinical characteristics and prognostic factors in Chinese patients with Hodgkin’s lymphoma Authors
First Online: 10 March 2011 Received: 20 February 2011 Accepted: 02 March 2011 DOI:
Cite this article as: Zhu, Y., Sun, Y., Xia, Y. et al. Med Oncol (2012) 29: 1127. doi:10.1007/s12032-011-9902-3 Abstract
The aim of our study is to investigate the clinical characteristics and prognostic factors in Chinese Hodgkin’s lymphoma patients. It is known that clinical characteristics and epidemiology of Hodgkin’s lymphoma in China are different from Western countries. In total, 137 consecutive, previously untreated patients with Hodgkin’s lymphoma at Sun Yat-Sen University Cancer Center were enrolled. Among these patients, 92 were male and 45 were female, with a median age of 28 (range: 2–76) years. The bimodal age curve of classical Hodgkin’s lymphoma analyzed from our patients was not obvious as the Western population, showing an early peak in 25 years and a second peak in 45 years. Most of the patients (41.6%) were classified as nodular sclerosis classic Hodgkin’s lymphoma. Results showed that the 5-year overall survival, event-free survival, and disease-free survival rates were 97.7, 85.0, and 94.0%, respectively. Lymphopenia at diagnosis was related to poorer overall survival (
P = 0.015) and event-free survival ( P < 0.001) in all-stage Hodgkin’s lymphoma patients. Multivariate analysis showed that lymphopenia as an independent unfavorable prognostic factor influenced event-free survival ( P = 0.015). The international prognostic score ≥ 5 was also the only independent prognostic factor of disease-free survival in advanced-stage patients ( P = 0.046). Our findings demonstrated that some clinical characteristics of Hodgkin’s lymphoma in China were different from those in the Western countries. Lymphopenia was an effective prognostic predictor in both early stage and advanced stage. Keywords Hodgkin’s lymphoma Prognosis Lymphopenia International prognostic score
Ying-Jie Zhu, Yue-Li Sun, Yi Xia authors contributed to this paper equally.
Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC; 2008.
Punnett A, Tsang RW, Hodgson DC. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol. 2010;20:30–44.
Glaser SL, Jarrett RF. The epidemiology of Hodgkin’s disease. Bailliere’s Clin Haematol. 1996;9:401–16.
Liang R, et al. Hodgkin’s disease in Hong Kong Chinese. Hematol Oncol. 1989;7:395–403.
Ji X, Li W. Malignant lymphomas in Beijing. J Environ Pathol Toxicol Oncol. 1992;11:327–9.
Aisenberg AC. Problems in Hodgkin’s disease management. Blood. 1999;93:761–79.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. New Engl J Med. 1998;339:1506–14.
Henry-Amar M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC lymphoma cooperative group. Ann Intern Med. 1991;114:361–5.
Tubiana M, et al. Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer. 1984;54:885–94.
Tubiana M, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC lymphoma group controlled clinical trials: 1964–1987. Blood. 1989;73:47–56.
Duhmke E, et al. Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys. 1996;36:305–10.
Cheson BD, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol 1999;17:1244.
Grillo-Lopez AJ, et al. Response criteria for NHL: importance of ‘normal’ lymph node size and correlations with response rates. Ann Oncol. 2000;11:399–408.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
Smolewski P, et al. Prognostic factors in Hodgkin’s disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res. 2000;6:1150–60.
Josting A, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin lymphoma study group. Blood. 2000;96:1280–6.
Tomita Y, et al. Epstein-Barr virus in Hodgkin’s disease patients in Japan. Cancer. 1996;77:186–92.
Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252–9.
Ferme C, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. New Engl J Med. 2007;357:1916–27.
Noordijk EM, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials. J Clin Oncol. 2006;24:3128–35.
Engert A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s lymphoma study group. J Clin Oncol. 2003;21:3601–8.
Herbst C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica. 2010;95:494–500.
Itoh K, et al. Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol. 2010;91:446–55.
Tan WY, et al. Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases. Ai zheng. 2007;26:1360–4.
Franklin J, et al. Is the international prognostic score for advanced stage Hodgkin’s disease applicable to early stage patients? German Hodgkin lymphoma study group. Ann Oncol. 2000;11:617–23.
Straus DJ, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990;8:1173–86.
Garcia R, et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease. Br J Cancer. 1993;68:1227–31.
Shipp M, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. New England J Med. 1993;329:987–94.
Siddiqui M, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol. 2006;134:596–601.
Behl D, et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol. 2007;137:409–15.
Kim DH, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007;21:2227–30.
Plonquet A, et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with a IPI 2–3 diffuse large B-cell lymphoma. Ann Oncol. 2007;18:1209–15.
Cox MC, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008;49:1745–51.
Oki Y, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol. 2008;81:448–53.
Porrata LF, et al. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol. 2009;84:93–7.
Ray-Coquard I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383–91.
Saito T, et al. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res. 1999;5:1263–73.
Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature. 1999;402:255–62.
PubMed CrossRef Copyright information
© Springer Science+Business Media, LLC 2011